Novartis AG will expand its research and sales force in China with its own employees, its chief executive officer said in an interview, despite a trend in the industry toward outsourcing in China…
"It should be a strategy owned by Novartis and directed by Novartis," said Joe Jimenez, who became the Swiss drug maker's chief executive in a sweeping February restructuring. Mr. Jimenez reiterated the company's four-year, $1 billion plan for a six-building research campus in Shanghai that could ultimately employ 500 scientists.
Also see #msg-27259204, which is dated but still germane.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”